Assignment task: You have treated a patient with a lung tumor bearing an EGFR mutation with gefitinib. After initial response, the patient has developed resistance to this drug. In the specific context of defined EGFR-dependent signaling cascades (i.e. including names of proteins that could be responsible), please describe
a. One potential mechanism of resistance arising from parallel activation
b. One potential mechanism of resistance from pathway bypass
c. One potential mechanism of resistance from pathway indifference; ALSO
d. What is one additional way that resistance could develop? AND
e. For each mechanism (a-d), please describe how you would test and confirm this mechanism was operative in mediating tumor resistance.